How to Get Your GLP-1 Cheaper in 2026: Savings Cards, Self-Pay & Telehealth

The list price of brand-name GLP-1 medications is roughly $1,000 to $1,350 per month, but the list price is almost never what people actually pay. As of 2026, Wegovy (semaglutide) and Zepbound (tirzepatide) carry list prices in that range, and Ozempic and Mounjaro — the versions approved for type 2 diabetes — are similar. What you pay depends entirely on three things: whether you have insurance, whether your specific plan covers the drug for your reason (weight versus diabetes), and which discount programs you qualify for. People with good coverage and a savings card might pay $0–$25 a month, while someone paying cash through a manufacturer's self-pay program might pay $349–$499, and only someone buying brand product fully out of pocket at retail would approach the four-figure sticker. Because pricing shifts frequently, the single most important habit is to verify the current price directly with the manufacturer's program and your pharmacy before assuming you cannot afford treatment. For a deeper look at coverage rules, see our guide on [whether insurance covers GLP-1 for weight loss](/blog/does-insurance-cover-glp1-for-weight-loss-2026).

Manufacturer savings cards (also called copay cards) are discount programs run by the drugmaker that lower your out-of-pocket cost if you have commercial insurance. Both Novo Nordisk (maker of Wegovy and Ozempic) and Eli Lilly (maker of Zepbound and Mounjaro) offer them. The way they work: if your commercial insurance covers the medication, the card can reduce your copay dramatically — often to as little as $0 to $25 per month, up to a monthly and annual cap. If your insurance does not cover the drug, these cards typically offer a smaller flat discount that still brings the price down from the full list price. The big catches to know: savings cards generally exclude people on government insurance like Medicare and Medicaid, they require a valid prescription, and the exact terms and dollar amounts change periodically. You enroll online through the manufacturer's website (NovoCare for Novo Nordisk drugs, the Zepbound/Mounjaro savings program for Lilly) in a few minutes. Always read the current eligibility terms, because they are updated regularly.

If you have no coverage or your plan excludes weight-loss drugs, direct self-pay programs from the manufacturers are usually the cheapest legitimate route. Eli Lilly's LillyDirect sells single-dose vials of Zepbound directly to cash-paying patients, and Novo Nordisk's NovoCare pharmacy offers self-pay Wegovy. As of 2026 these vial programs run roughly $349 to $499 per month depending on dose and which program — a major discount from the $1,000-plus list price. These vials require drawing the dose with a syringe rather than using a prefilled pen, which is the trade-off for the lower price. This is also a far safer and more transparent option than unregulated sources online. Some people explore compounded GLP-1s, which can be cheaper still, but quality and legality vary considerably; read our breakdown of [compounded vs brand GLP-1 safety](/blog/compounded-vs-brand-glp1-is-cheaper-option-safe-2026) before going that route. Whatever you choose, buy only from licensed pharmacies tied to the manufacturer or a legitimate prescriber.

Yes — FSA and HSA accounts and telehealth providers are two of the most overlooked ways to cut your real GLP-1 cost. A Flexible Spending Account (FSA) or Health Savings Account (HSA) lets you pay for prescription medications with pre-tax dollars. Because you avoid income tax on that money, using FSA/HSA funds effectively reduces your cost by roughly 20–35%, depending on your tax bracket — a GLP-1 prescription is an eligible expense when prescribed by a clinician. Telehealth platforms can help in a different way: they provide convenient access to a prescriber, often bundle the medication (frequently compounded or self-pay versions) into a flat monthly fee, and handle the prescription logistics. Pricing and quality among telehealth providers vary widely, so compare what is actually included — the consult, the medication, dose changes, and ongoing support — rather than just the headline price. Combining strategies (for example, FSA dollars plus a savings card, or a telehealth self-pay plan) often produces the lowest realistic cost.

Yes — both major manufacturers run Patient Assistance Programs (PAPs) that provide medication free or at deep discount to people who qualify based on income and lack of coverage. These are separate from savings cards and are intended for those with limited financial resources, often the uninsured. Eligibility is income-based and requires an application with documentation, and approval is not guaranteed, but for someone who cannot afford any of the options above, a PAP can be the difference between treatment and none. Nonprofit prescription-assistance organizations and your prescriber's office can also help you find foundation grants or local programs. It is worth applying even if you are unsure you qualify, because the potential savings — a fully covered prescription — is large. The bottom line across all of these options: the published list price should not be the reason you rule out GLP-1 treatment, because most people have a path to pay far less.

Confused by savings cards, self-pay, and telehealth options? Lea can walk you through which path fits your insurance and budget, and help you prepare the questions to ask your pharmacy and prescriber.